Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

Regorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% treated patients achieve disease stabilisation or better at the first radiological evaluation. In add...

Descripción completa

Detalles Bibliográficos
Autores principales: Giampieri, Riccardo, Prete, Michela del, Prochilo, Tiziana, Puzzoni, Marco, Pusceddu, Valeria, Pani, Fabiana, Maccaroni, Elena, Mascia, Roberta, Baleani, Maria Giuditta, Meletani, Tania, Berardi, Rossana, Lanzillo, Anna Maria, Mariotti, Stefano, Zaniboni, Alberto, Cascinu, Stefano, Scartozzi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380985/
https://www.ncbi.nlm.nih.gov/pubmed/28378839
http://dx.doi.org/10.1038/srep45703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380985/
https://www.ncbi.nlm.nih.gov/pubmed/28378839
http://dx.doi.org/10.1038/srep45703

Ejemplares similares